← Back to headlines
CRISPR Therapeutics Shares Promising Early Data for Cholesterol Gene Therapy
CRISPR Therapeutics has presented initial clinical trial results for CTX310, a gene-editing treatment aimed at lowering triglycerides and LDL cholesterol, showing durable genetic modifications at the European Society of Cardiology congress.
28 Aug, 14:31 — 28 Aug, 14:36
The Story
Analyzing sources…
Source Diversity
Source Diversity
Low (24/100)2 sources— more sources would strengthen this score15/33
Spectrum spread— 1/5 buckets covered0/33
Far L
Left
Center2
Center (2)
investing-comtaiwan-news
Right
Far R
Geographic diversity— 2 regions9/34
US1Taiwan1
ℹOnly 2 sources cover this story
Sources
Showing 2 of 2 sources
investing-com17h ago
CRISPR Therapeutics reports one-year data for gene therapy CTX310
By Investing.com
Read full article →taiwan-newsMostly Factual17h ago
CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026 - Taiwan News
CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026 Taiwan News
Read full article →Coverage Timeline
First report: taiwan-news · 28 Aug, 14:31|Full coverage: 2 · 6m|Window: 6m
Left-leaningCenterRight-leaning
Related Stories
Chinese Chipmaker CXMT Sues Pentagon Over Military Designation
4h ago
AI Demand Fuels Record Chipmaker Profits Amid Broader Cost Pressures
10h ago
Rockstar Unveils Grand Theft Auto VI Details Ahead of Major Release
10h ago
Nvidia Reports Record Earnings and Raises Revenue Forecast Amid AI Demand Surge
10h ago